Background Depressive symptoms are a major cause of disability in bipolar disorder and there are few safe and eff ective treatments. The combination of lamotrigine plus quetiapine potentially off ers improved outcomes for people with bipolar depression. We aimed to determine if combination therapy with quetiapine plus lamotrigine leads to greater improvement in depressive symptoms over 12 weeks than quetiapine monotherapy plus lamotrigine placebo.
Introduction
Bipolar disorder, an illness characterised by recurrent depressive and manic episodes, is among the most important causes of worldwide disability. 1 The burden of depressive, rather than manic, symptoms causes most of the long-term disability and excess mortality in people with bipolar disorder. 2 Evidence for eff ective short-term and longer-term treatment options for bipolar depression remain restricted. 3 Recent UK National Institute for Health and Care Excellence guidelines recommend fl uoxetine plus olanzapine combination or quetiapine as fi rst-line treatment. 4 The evidence for antidepressant drugs such as fl uoxetine in bipolar depression, however, remains controversial, with no consensus that they are either eff ective or safe. 5 Many patients do not respond to these interventions and the evidence for effi cacy and tolerability of longerterm quetiapine is scarce. 3 Lamotrigine is widely used as an antiepileptic. It is an inhibitor of voltage-sensitive sodium channels, and is thought to work by reducing presynaptic release of glutamate, although its mechanism of action in bipolar disorder remains unclear. 6 Clinical observation of a benefi cial eff ect in depression led to investigation in bipolar disorder, which showed effi cacy in the prevention of depressive relapse. 7 Lamotrigine is now licensed in the USA and the European Union for the prevention of relapse in patients with bipolar type 1 disorder who have predominantly depressive episodes. 8 There has been considerable uncertainly, however, around the effi cacy of lamotrigine monotherapy in the acute phase of bipolar depression. A modest treatment eff ect was observed in pooled analysis, but not seen in individual trials, which could be because the trials were of short (8 week) duration and lamotrigine requires a lengthy 6-week titration period, which means that the participants had been taking a full therapeutic dose for only 2 weeks at the time that the primary outcome was assessed. 9 The LamLit trial noted signifi cant benefi t at 8 weeks for the addition of lamotrigine to lithium therapy in patients with bipolar depression. 10 Current monotherapies for bipolar depression remain restricted in terms of both proven effi cacy and practical tolerability, but combinations of treatments might lead to improved outcomes. This trial was designed to test the hypothesis that a strategy of combining lamotrigine with quetiapine might lead to better short-term response and longer-term outcomes than quetiapine alone. Additive benefi ts from the combination might, of course, result from their independent mechanisms of action, because the two drugs have entirely diff erent pharmacologies. Further, the rapid onset of the therapeutic eff ects of quetiapine could make the slow-dose titration required for lamotrigine less problematic: more patients would remain on therapy and therefore benefi t from the therapeutic potential of lamotrigine in the acute phase. There could also be important advantages in the longer term since patients on the combination who cannot tolerate the known adverse eff ects of quetiapine would remain on an eff ective drug following its discontinuation, 3 leading to a functional synergy between lamotrigine and quetiapine.
The primary objective was to determine if combination therapy with quetiapine plus lamotrigine leads to greater improvement in depressive symptoms over 12 weeks than quetiapine monotherapy plus lamotrigine placebo in patients with bipolar depression. By using a factorial design, we also investigated the eff ects of addition of folic acid, which is a simple, widely available, over-thecounter treatment, for which there is some evidence of effi cacy in unipolar depression. 11 Furthermore, folic acid is often included in vitamin pills as well as being recommended during pregnancy especially when women are taking lamotrigine.
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Methods
Study design and participants
CEQUEL was a double-blind, randomised, placebocontrolled, parallel group, 2 × 2 factorial trial undertaken across 27 sites in the UK (fi gure 1). The trial protocol is available from JRG. Eligible patients had bipolar disorder I or II diagnosed according to DSM-IV 13 criteria on the basis of clinician interview, required new pharmacological treatment for an acute depressive episode, gave informed consent, and were aged 16 years or older (appendix). Additional criteria for entry to the randomised phase included ability to tolerate quetiapine at a dose of at least 150 mg/day; uncertainty whether quetiapine plus lamotrigine would be more eff ective than quetiapine monotherapy; acceptable adherence to quetiapine (>90%); and were responding to the prompts to provide outcome data; willing to accept random allocation of treatments; and in the opinion of the investigator, not currently experiencing manic or mixed episode.
Written informed consent was obtained from every patient. The study was approved by each centre.
A number of protocol changes were made during the trial, all of which were approved by the Oxfordshire REC B ethics committee. The protocol initially approved was version 02. Protocol version 03 (December, 2008) included changes to procedures for distributing the investigational medicinal product. Protocol version 04 (March, 2009) included the addition of questions relating to use of health and social care resources and dose of lamotrigine 400 mg/day for women taking oral con traceptives. Version 05 included a change to primary outcome from binary "remission at 12 weeks" to con tinuous "greater improvement in depressive symptoms over 12 weeks", a consequent reduction in sample size from 584 to 236 and to allow immediate randomisation of patients already on quetiapine. Version 06 (May, 2013) included investigation of the eff ect of the folate hydrolase polymorphism on folic acid.
Randomisation and masking
After 7-14 days run-in on quetiapine, participants were randomly assigned (1:1) to added lamotrigine
Research in context
Evidence before this study During the planning phase of CEQUEL, we conducted a systematic review and individual patient data meta-analysis of randomised trials (Geddes et al, 2009 ). The pooled analysis found a modest treatment eff ect for lamotrigine over an 8 week period which was not observed in the individual trials.
Added value of this study CEQUEL investigated the eff ect of lamotrigine compared with placebo over a longer time period than previous trials and as add-on therapy to quetiapine. CEQUEL also investigated the eff ects of folic acid compared to placebo in bipolar depression.
Implications of all the available evidence
Lamotrigine improves depressive symptoms in bipolar depression and the benefi ts are maintained for 52 weeks. Adding lamotrigine to quetiapine might be an eff ective and well tolerated option for many patients with bipolar depression. Folic acid may reduce the effi cacy of lamotrigine. Lamotrigine also reduced the risk of relapse in patients with bipolar 1 disorder who have predominantly depressive episodes. CEQUEL should encourage clinicians and patients to consider lamotrigine for bipolar depression, but also to be aware that concurrent folic acid might reduce its eff ectiveness.
See Online for appendix 200 mg/day (100 mg/day with concurrent valproate and 400 mg/day with concurrent combined oral contraceptives) or placebo by a centralised randomisation service by fax or web-based form. Lamotrigine was commenced at 25 mg daily and increased gradually to 200 mg as in the US FDA prescribing information. 14 Participants, clinicians, and researchers were masked to treatment allocation.
Participants not currently taking folic acid and with no contraindications to it were separately randomised to folic acid 500 μg/day or placebo. To enroll a patient, the treating physician faxed the randomisation form to the trial offi ce. After establishing eligibility and that informed consent had been obtained, the patient was randomised, assigned a treatment pack number, and dispensed medication from the trial pharmacy. Randomisation used an adaptive minimisation algorithm balancing for centre, age, sex, bipolar disorder I or II, baseline severity of depression, quetiapine dose, concurrent medication, pretrial use of quetiapine, pretrial use of lamotrigine, and mood episodes in past year (<4 or ≥4). The minimisation algorithm was seeded by randomising the fi rst 60 participants using simple randomisation then introducing the minimisation algorithm. Allocated treatment was continued for 52 weeks and follow-up was continued even if trial-allocated treatment was discontinued.
Procedures
The severity of depressive symptoms was assessed with the Quick Inventory of Depressive Symptomatology-self report version (QIDS-SR16), which is a 16-item scale covering the DSM-IV criteria for depressive episode producing a score between 0 and 27. 15 The QIDS-SR16 has been shown to agree well with the clinician-rated version in patients with bipolar depression and with other widely used depression rating scales such as the 24-item Hamilton Rating Scale for Depression. [15] [16] [17] [18] QIDS-SR16 scores are categorised: ≤5 as no depression; 6-10 as mild depression; 11-15 as moderate depression; 16-20 as severe depression; and ≥21 as very severe depression. A minimum level of depressive symptoms was not required for entry to either run-in or randomised phases of the trial because the relevant criterion was clinical judgement that new pharmacological treatment was required for a depressive episode. Manic symptoms were assessed with the Altman Self Rating Mania Scale (ASRM). 19 Quality of life was measured at baseline and at 12 weeks and 52 weeks with the EuroQol EQ-5D-3L. 20 Data for symptoms and quality of life were provided by participants by the True Colours system via text message, email, or paper. 21 Investigators were encouraged to withdraw any other treatments for mood symptoms that participants were taking before entry to the run-in phase, but these drugs could be continued where clinically indicated. Drug treatments that were not withdrawn were continued at the same dose for the duration of the trial unless there was a clinical need for change. All concurrent psychotropic medicines were recorded on the baseline assessment form and any subsequent changes reported. Carbamazepine (which decreases the serum level of lamotrigine) was stopped during the run-in phase or replaced by oxcarbazepine.
Additional treatment for depressive symptoms was not allowed during the fi rst 12 weeks of the randomised phase. After 12 weeks, new treatment for depressive symptoms could be initiated as clinically appropriate if a response to allocated treatment was considered to be inadequate or if new symptoms emerged. Folic acid (prescribed and over-the-counter preparations) was stopped unless there were reasons why the participant should not be randomised to folic acid or placebo.
All participants initially entered a 7-14 day active runin with quetiapine monotherapy to screen for adherence to quetiapine and to study procedures, tolerability, and symptom stability. Quetiapine was commenced at 50 mg on days 1 and 2, increased to 100 mg on days 3 and 4, 200 mg on days 5 and 6, and 300 mg on day 7 and beyond. The target dose of quetiapine was 300 mg, but if this was not tolerated a minimum dose of 150 mg was required for at least 3 days to proceed to randomisation. Quetiapine was continued at the established dose throughout the randomised phase unless there were clinical reasons to stop or the patient withdrew consent. Changes to the dose of quetiapine after randomisation were considered to be protocol non-compliant and when this occured the reason for the change was recorded. The run-in was included both to exclude patients with transient symptoms and to improve effi ciency without jeopardising clinical applicability by deploying the combination in a stepped approach comparable with routine clinical practice. 22 The fi rst participant was recruited on Oct 21, 2008 , and the last patient completed follow-up on April 27, 2013. We also genotyped functional polymorphisms in genes involved in one-carbon pathways, and measured related biochemical indices; these results will be presented separately.
Outcomes
The primary outcome was depressive symptoms score at 12 weeks (±2 weeks) from randomisation using QIDS-SR16. The prespecifi ed primary analysis was assessed via a linear mixed eff ects model using data at 12 weeks (±2), 22 (±2) weeks, and 52 (±2) weeks only. The model fi tted time and randomised group as fi xed eff ects and participants as random eff ect. An interaction between time and randomised group was fi tted to allow estimation of treatment eff ect at each timepoint. Analysis was by modifi ed intention-to-treat. That is, after randomisation, participants were analysed according to their allocated treatment group irrespective of what treatment they actually received. Assumptions for regression models were assessed graphically based on residuals. Participants who provided no data within these time windows were excluded. The model was adjusted for folic acid (active, placebo, or not allocated), baseline QIDS-SR16, baseline ASRM (≥6), bipolar disorder I or II, age, sex, dose of quetiapine (<300 mg/day or ≥300 mg/day), concurrent lithium, concurrent valproate, or concurrent antidepressant. The primary analysis of the folic acid comparison was conducted in the same way as for the lamotrigine comparison, but included only those randomised to the folic acid part of the study. Although an interaction between the interventions was not anticipated, this was investigated by adding an interaction term between the randomised treatments (lamotrigine x folic acid) to the model in the analysis of the primary outcome. The interaction analysis was restricted to participants who were randomised to both lamotrigine/placebo and folic acid/ placebo. In line with the primary analysis, a regression based approach adjusting for covariates was applied both for the lamotrigine and folic acid comparisons.
As a secondary analysis of the primary outcome, all weekly non-missing QIDS-SR16 scores between randomisation and week 52 were analysed with a mixed eff ects linear regression model to account for the repeated measures over time. The mixed eff ect model contained QIDS-SR16 score as the response variable, and time (week) as a continuous covariate to allow the slope of the regression line representing the change in outcome over time to be assessed. A time by lamotrigine interaction was included as a fi xed eff ect to allow estimation of the slope of the regression line to diff er according to treatment allocation. Treatment eff ect at each timepoint was derived similarly as described above. To incorporate the noted absence of linearity into the analysis, the regression model was segmented at 12 weeks and 22 weeks and the slope at each point was allowed to vary.
Secondary outcomes included improvement in depressive symptoms at 52 weeks; proportion of participants in remission (QIDS-SR16 ≤5) at 12 weeks and 52 weeks; time to new intervention for depressive and manic symptoms; self-harm; mortality; adverse events; and health-related quality of life. EQ-5D utility analyses were based on available cases and following multiple imputation of missing data.
The proportion of participants with manic symptoms, defi ned as ASRM scores 6 or higher at 12 weeks, 22 weeks, and 52 weeks after randomisation, was analysed with log-binomial regression models at each timepoint separately. The models included treatment by lamotrigine, treatment by folic acid (yes, no, or not applicable) and minimisation variables as for the primary analysis.
Statistical analysis
The sample size was calculated to detect a clinically important eff ect of lamotrigine on the primary outcome measure-ie, a 2·0 point diff erence (SD 5·4) in the QIDS-SR16. The calculation assumed a repeated measures analysis with 3 timepoints and a correlation between time points of 0·4 and also included a 20% loss to follow-up, yielding a total sample size of 236 (90% power and two-sided alpha 5%).
Data were analysed with SAS version 9.3 (SAS Institute Inc, Cary, NC, USA). 
Role of the funding source
This study was funded by the Medical Research Council. Some study drug was donated by GlaxoSmithKline. Neither funder had any role in the study design; data collection, analysis, or interpretation of data; writing of the report; or in the decision to submit the paper for publication.
Results
Between Oct 21, 2008, and April 27, 2012, 202 participants were randomly assigned; 101 to lamotrigine and 101 to placebo (fi gure 1). Of 266 participants who entered the run-in, 19 (7%) were unable to progress to randomisation due to adverse eff ects or inability to tolerate quetiapine. Baseline characteristics of randomised participants are summarised in table 1; about three-quarters of patients met criteria for bipolar type I. The aim was to balance groups for bipolar subtype, age, and sex, but some imbalances remained. The largest imbalance was the proportion using antidepressants at randomisation: more participants randomised to placebo were using antidepressants compared with those randomised to lamotrigine. The direction of imbalance was reversed for the folic acid comparison, with slightly fewer participants using antidepressants at baseline in those who were randomised to placebo compared with those randomised to folic acid. Analyses were adjusted for these imbalances. About three quarters of participants were diagnosed with bipolar disease I and a quarter were diagnosed with bipolar disease II and the mean QIDS-SR16 score indicates moderate depression. The modal daily dose of quetiapine was 300 mg/day. At 12 weeks, participants randomised to lamotrigine had lower QIDS-SR16 scores than those randomised to placebo (table 2; table 3 ; fi gure 2A). The mean diff erence between the groups was -1·73 points ([95% CI -3·57 to 0·11]; p=0·066). A similar diff erence was seen at 22 weeks (-1·87 points [-3·92 to 0·17]; p=0·072; table 3; fi gure 2B). At 52 weeks, participants randomised to lamotrigine were on average 2·7 points lower on the QIDS scale (-2·69 ([95% CI -4·89 to -0·49]; p=0·017) than those randomised to placebo. Thus, mean QIDS-SR16 scores were consistently lower in participants taking lamotrigine than in those taking placebo (table 3) .
Signifi cantly more participants treated with lamotrigine met criteria for remission ( The secondary analysis of the primary outcome, using all submitted scores over the 52 week follow up period resulted in similar fi ndings (data not shown). Depression scores decreased for those receiving lamotrigine more quickly than those receiving placebo resulting in an estimated diff erence at 12 weeks of -1·40 ([95% CI -2·9 to 0·09]; p=0·066).
150 participants (all those available who were randomly assignedto folic acid study) were available for analysis of folic acid versus placebo at 12 weeks. Mean QIDS-SR16 scores were no diff erent in those randomly assigned to folic acid than in those randomly assigned to placebo at 12 weeks or at 22 weeks and 52 weeks (table 2; fi gure 2B).
Although an interaction between lamotrigine and folic acid had not been anticipated, it seemed that folic acid was associated with an impaired lamotrigine response in the fi rst 12 weeks.
Due to the interaction noted between treatments, the most reliable and unconfounded estimate of the eff ect of lamotrigine at 12 weeks is the estimate from the group not randomised to take folic acid. At 12 weeks, the mean diff erence in QIDS-SR16 on lamotrigine compared with placebo was -4·14 ([95% CI -6·90 to -1·37]; p=0·004) with no folic acid and 0·12 ([-2·58 to 2·82]; p=0·931) with folic acid (fi gure 3).
There were no signifi cant diff erences in rates of new treatment (hospital admission or drug treatment) for depression between the treatment groups (31 [31%] in During the 12 months follow-up, health-related quality of life improved in all groups generally. No diff erence was seen for any of the group comparisons (appendix pp 3-4).
There were 32 serious adverse events in 24 randomised participants. These included one death by suicide (in the folic acid only group), 18 admissions to hospital for depression, mania, or other mood disorders involving 15 participants (six participants allocated placebo only, three participants allocated lamotrigine only, two participants allocated folic acid only, and four participants allocated lamotrigine plus folic acid); and 13 admissions to hospital in nine participants for other reasons; (three participants allocated placebo only, two participants allocated lamotrigine only, one participant allocated folic acid only, and three participants allocated lamotrigine plus folic acid). None were judged to be related to trial medication.
There were 17 non-serious adverse events that led to withdrawal of treatment in 17 participants. Five were judged to be possible adverse reactions to trial medication (one participant allocated placebo only, two participants allocated lamotrigine only, one participant allocated folic acid only, and one participant allocated lamotrigine plus folic acid). Symptoms included nausea and stomach cramps, musculoskeletal pain, and oedema. For 12 participants, the adverse event was judged to be unrelated to trial medication (fi ve participants allocated placebo only, three participants allocated lamotrigine only, two participants allocated folic acid only and two participant allocated lamotrigine plus folic acid. Table 2 shows the number of participants included at each timepoint but there are no data for adherence to treatment.
Discussion
The results of CEQUEL show that addition of lamotrigine to quetiapine for treatment of acute bipolar depression improves both mean depressive symptoms and rates of clinical remission compared with placebo at 12 weeks and 52 weeks. Folic acid was no better than placebo in reducing depressive symptoms. There was a statistically signifi cant interaction between lamotrigine and folic acid at 12 weeks, with folic acid seeming to substantially reduce the eff ectiveness of lamotrigine. The result of this eff ect modifi cation was that the mean diff erence in QIDS-SR16 due to lamotrigine was reduced in the full sample (including participants on both active folic acid and folic acid placebo). Restricting the analysis at 12 weeks to those participants not allocated to folic acid produced an unbiased estimate of the eff ect of lamotrigine, which showed a statistically and clinically signifi cant mean reduction of 4·1 points (95% CI 1·37-6·90) on the QIDS-SR16, although the smaller sample size led to greater imprecision around the treatment eff ect. No benefi ts due to lamotrigine were observed on the secondary outcome measure of health-related quality of life, which might be due to lack of power.
The strengths of CEQUEL include the double-blind design and good retention rates (>80%) at 12 weeks. Almost all the patients recruited into CEQUEL were receiving lamotrigine for the fi rst time, which is a substantial strength of the study because the results are therefore able to inform treatment decisions in patients who have not had experience of the drug. The main weakness is the higher drop-out rate at 52 weeks, although this remains lower than often observed even in double-blind maintenance trials in this clinical population. 23 Factorial trials, which can be an effi cient way to evaluate two or more interventions, uncommonly identify interactions between treatments. 24, 25 In CEQUEL, there was a statistically and clinically signifi cant interaction, which shows some of the advantages and disadvantages of this design. The interaction between folic acid and lamotrigine was unexpected and additional research is required to investigate this further. However, there are grounds to consider such an interaction biologically plausible. Lamotrigine was originally synthesised as one of a series of folate antagonists on the grounds that folate was thought to be pro-convulsant. 6 Hence, it is possible that lamotrigine and folate both bind to a common receptor or enzyme site. Alternatively, it could be a pharmacokinetic eff ect whereby folic acid reduces absorption of lamotrigine from the gastrointestinal tract. There has been surprisingly little research into the mechanism(s) of action of lamotrigine to either include or exclude a possible important eff ect modifi cation by folic acid. We cannot fi nd any previous report of a clinical interaction of the kind we describe here, although the summary of product characteristics for lamotrigine does report an eff ect on folate levels. Whatever the cause, the interaction is potentially clinically important because folic acid supplementation might be more likely in some patient groups taking lamotrigine, for example pregnant women 12 and as an adjunctive therapy in mood disorder. 11 Furthermore, folic acid is present in the doses used in CEQUEL in many over-the-counter vitamin preparations. One clinically important conclusion from CEQUEL is that if a patient with bipolar disorder needs folic acid therapy, then lamotrigine should be avoided (and vice versa). The result raises an intriguing question about the likely effi cacy of lamotrigine in countries which fortify wheat fl ower with folic acid: the US programme has been estimated to provide 100-200 μg of folic acid per day in women of childbearing age. 27 It is unclear if this amount is suffi cient to reduce the treatment eff ect.
CEQUEL confi rms the effi cacy, in the absence of folic acid, of adding lamotrigine to quetiapine in bipolar depression and that the benefi ts persist for 52 weeks. These fi ndings complement another independent trial, which showed clinical benefi t for lamotrigine combination therapy, although in that case in combination with lithium. 10 Together with the pooled data of lamotrigine versus placebo, 9 it seems that lamotrigine is an eff ective treatment in bipolar depression. Guidelines have varied in their recommendation of lamotrigine as a fi rst choice option for treating bipolar depression because of the uncertainties remaining from the industry sponsored trials. They either suggest using lamotrigine monotherapy as a fi rst line treatment option 28 or as a second line option or following non-response to initial therapy. 4 CEQUEL is an important addition to the evidence base that informs clinical practice because it suggests that adding lamotrigine to quetiapine may be an eff ective and well tolerated option for many patients with bipolar depression.
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